Urticaria

CHRONIC URTICARIA​

Treatment​

Omalizumab​

Drug Survival

Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation. JAMA Dermatol 2024. PMID: 39018068.​

• At 1 year 76% are still on the medication, at 3 years ~53%, at 5 years 43%, and at 7 years 39%.

• The main reason for discontinuation of omalizumab was disease control.  The median time on drug was 3.3 years and almost 2/3rds will discontinue because of disease control (for patients, "half of patients discontinue it by about 3 years, and half are on it for more than 3 years.  Of those stopping the medication, 2/3rds do so because of disease control).  

• Presence of disease for 2 or more years and chronic inducible urticaria subtypes were associated with a lower chance of discontinuation. 

• Patients with a good response by 1 month were almost 50% more likely to discontinue due to well-controlled disease. 

​

​

​

​